Advanced Biomedical Technologies Stock Beta
| ABMT Stock | USD 0.0001 0.00 0.00% |
Advanced Biomedical's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Advanced Pink Sheet price.
Advanced |
Advanced Biomedical Technologies Company Beta Analysis
Advanced Biomedical's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Advanced Biomedical Beta | 0.63 |
Most of Advanced Biomedical's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Advanced Biomedical Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Advanced Biomedical Technologies has a Beta of 0.6287. This is 26.9% lower than that of the Health Care Equipment & Supplies sector and 39.55% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Advanced Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Advanced Biomedical's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Advanced Biomedical could also be used in its relative valuation, which is a method of valuing Advanced Biomedical by comparing valuation metrics of similar companies.Advanced Biomedical is currently under evaluation in beta category among its peers.
As returns on the market increase, Advanced Biomedical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Advanced Biomedical is expected to be smaller as well.
Advanced Fundamentals
| Return On Asset | -0.78 | |||
| Operating Margin | (3.86) % | |||
| Current Valuation | 3.52 M | |||
| Shares Outstanding | 70.22 M | |||
| Shares Owned By Insiders | 3.32 % | |||
| Price To Earning | (12.00) X | |||
| Price To Sales | 31.97 X | |||
| Revenue | 123.59 K | |||
| Gross Profit | 71.77 K | |||
| EBITDA | (282.69 K) | |||
| Net Income | (672 K) | |||
| Cash And Equivalents | 6.98 K | |||
| Total Debt | 6.36 M | |||
| Debt To Equity | (1.04) % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | 646.66 K | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 17 | |||
| Beta | 0.63 | |||
| Market Capitalization | 4.14 M | |||
| Total Asset | 469.23 K | |||
| Retained Earnings | (2.88 M) | |||
| Working Capital | (4.38 M) | |||
| Current Asset | 34 K | |||
| Current Liabilities | 4.42 M | |||
| Z Score | -19.2 | |||
| Net Asset | 469.23 K |
About Advanced Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Advanced Biomedical Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Advanced Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Advanced Biomedical Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Advanced Pink Sheet Analysis
When running Advanced Biomedical's price analysis, check to measure Advanced Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Advanced Biomedical is operating at the current time. Most of Advanced Biomedical's value examination focuses on studying past and present price action to predict the probability of Advanced Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Advanced Biomedical's price. Additionally, you may evaluate how the addition of Advanced Biomedical to your portfolios can decrease your overall portfolio volatility.